IN Brief:
- DHL will add a 3,047-square-metre dedicated healthcare facility inside Changi Airfreight Centre.
- The operation will support 2°C–8°C and 15°C–25°C cargo with monitored, GDP-designed infrastructure.
- Completion in 2027 forms part of DHL's €2 billion global healthcare logistics investment programme.
DHL Global Forwarding is establishing a dedicated healthcare logistics facility at Singapore Changi Airport, adding temperature-controlled capacity for pharmaceutical and life sciences cargo moving through one of Asia-Pacific’s major airfreight hubs. The 3,047-square-metre DHL Singapore Coldchain Hub is due for completion by the end of 2027.
The facility will be located in Changi Nexus One within the Changi Airfreight Centre and designed in accordance with Good Distribution Practice standards. It will support controlled-temperature shipments in the 2°C to 8°C and 15°C to 25°C ranges, with GDP-qualified cold rooms, real-time temperature monitoring, and direct airside connectivity.
DHL also plans dedicated temperature-controlled transfers between aircraft, the new facility, and customer warehouses. Pharmaceutical logistics cannot maintain a validated environment solely inside the warehouse: aircraft unloading, apron dwell time, ground transport, customs processes, and handovers all create points at which sensitive cargo can move outside its required range.
Changi already has more than 9,000 square metres of airside-fronting temperature-controlled handling space with capacity exceeding 375,000 tonnes per year. Thermal-protection equipment, including cool dollies, is used on the apron, while Nexus One provides close to 8,000 square metres of warehousing with direct apron connectivity.
The DHL operation therefore adds specialist capacity inside an established temperature-controlled airport ecosystem rather than creating a standalone cold store away from the airfreight process. Direct access can reduce handling steps between aircraft and controlled storage, which is particularly valuable for high-value medicines where time, temperature, chain of custody, and documented handling conditions have to remain aligned.
Demand is being driven by pharmaceutical market growth and a product mix with increasingly exacting logistics requirements. An IQVIA outlook cited by Changi forecasts pharmaceutical sales across 12 key Asian markets, including China, Japan, India, South Korea, and Singapore, to grow at a compound annual rate of 3.7% between 2024 and 2029.
Singapore’s pharmaceutical cold chain volumes are projected to rise from 14 million kilograms in 2028 to 17 million kilograms in 2031, equivalent to roughly 7% annualised growth. DHL is therefore committing capacity before the later-decade increase in throughput is expected to materialise.
The Changi development also sits within DHL Group’s €2 billion investment programme for life sciences and healthcare through 2030. A quarter of that investment was allocated to Asia-Pacific when the programme was announced, with spending directed towards GDP-certified pharma hubs, temperature-controlled vehicles, packaging, IT systems, storage, and distribution capabilities.
DHL is pursuing the same specialist-infrastructure approach elsewhere. In the UK, a planned healthcare hub at Infinity Park Derby combines multi-temperature storage with high-density automation, while the Singapore project is more closely tied to airfreight transfer and regional pharmaceutical flows. Both place dedicated healthcare infrastructure at the centre of the operation rather than reserving a small controlled zone within a general warehouse.
Biologics, specialty medicines, clinical-trial materials, and advanced therapies strengthen the case for that separation. Such products can be relatively small in physical volume but expensive, temperature-sensitive, and difficult to replace quickly. A failed consignment can therefore create a much larger operational and financial consequence than its freight spend suggests.
Singapore’s gateway role adds another layer. Changi connects directly to about 170 cities, with close to 100 airlines operating more than 7,100 flights a week, giving forwarders multiple routing options for time-sensitive cargo. That network depth can support contingency planning only if the physical transfer infrastructure maintains equivalent control when cargo changes aircraft, handlers, or transport modes.
The project also reflects the long lead times attached to specialist logistics capacity. Completion is targeted for the end of 2027, while the pharmaceutical-flow forecasts cited for Singapore extend into 2031. Building ahead of demand gives DHL time to commission the facility and establish qualified processes before volumes reach their later-decade levels. That commissioning period also gives customers time to qualify lanes and operating procedures before volumes scale.
Once operating, the hub will be judged on the integrity of the complete transfer chain rather than its floor area. Direct apron access, qualified rooms, monitored conditions, and controlled onward transport are intended to reduce weak points between aircraft and warehouse — the stages at which a pharmaceutical shipment either remains inside specification or becomes an expensive exception.
